BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:19 PM
 | 
Mar 19, 2007
 |  BC Extra  |  Clinical News

Avexa's apricitabine meets HIV endpoint

Avexa (ASX:AVX) said apricitabine met the primary endpoint in the Phase IIb AVX-201 trial to treat HIV...

Read the full 65 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >